Ulrich B. Keller

Berlin, BE, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 305 publications

Blinatumomab in refractory SLE-associated immune thrombocytopenia.

Blinatumomab in refractory SLE-associated immune thrombocytopenia.

Journal: Annals of the rheumatic diseases
Published: July 01, 2026

Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma.

Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma.

Journal: Haematologica
Published: April 15, 2026

CXCR4-Targeted Molecular Imaging in Hematology and Oncology.

CXCR4-Targeted Molecular Imaging in Hematology and Oncology.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: March 22, 2026

CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial.

CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial.

Journal: Nature medicine
Published: March 20, 2026

Clonal Hematopoiesis does not influence manufacturing of Chimeric Antigen Receptor (CAR) T-Cells.

Clonal Hematopoiesis does not influence manufacturing of Chimeric Antigen Receptor (CAR) T-Cells.

Journal: Bone marrow transplantation
Published: February 19, 2026

High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial.

High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial.

Journal: Lancet (London, England)
Published: February 19, 2026

Liquid biopsy-based detection of acquired MET resistance enables sequential targeted therapy in MET fusion-positive NSCLC.

Liquid biopsy-based detection of acquired MET resistance enables sequential targeted therapy in MET fusion-positive NSCLC.

Journal: The oncologist
Published: February 13, 2026

Functional immune profiling translates T cell dynamics into predictive biomarkers for myeloma immunotherapy.

Functional immune profiling translates T cell dynamics into predictive biomarkers for myeloma immunotherapy.

Journal: Leukemia
Published: February 12, 2026

Feasibility and safety of rapid glofitamab ramp-up.

Feasibility and safety of rapid glofitamab ramp-up.

Journal: Leukemia
Published: January 20, 2026

Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis-a case series.

Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis-a case series.

Journal: Annals of the rheumatic diseases
Published: January 19, 2026

Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series.

Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series.

Journal: Annals of the rheumatic diseases
Published: January 19, 2026

Comprehensive molecular analyses for diagnosis and treatment guidance in an adult neuroblastoma patient.

Comprehensive molecular analyses for diagnosis and treatment guidance in an adult neuroblastoma patient.

Journal: The oncologist
Published: December 23, 2025
Showing 1-12 of 305

Last Updated: 09/26/2026